Autologous Bone Marrow Stem Cell Transplantation in Patients With Subacute Spinal Cord Injury

Spinal Cord Injuries Clinical Trial

Official title:

Phase 2, Double- Blind, Placebo- Controlled , Randomized Clinical Trial of Autologous Bone Marrow Stem Cell Transplantation in Patients With Subacute Spinal Cord Injury

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05671796
• Other study ID #: PLC01/2021
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 1, 2023
• Est. completion date: December 1, 2023

Study information

• Verified date: January 2023
• Source: SENAI CIMATEC
• Contact: Carolina Macedo, PhD
• Phone: 557138795574
• Email: carolthemacedo[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and safety of intrathecal administration of autologous mesenchymal stem cells in participants with subacute spinal cord injury.

Description:

Spinal cord injury (SCI) constitutes a social and economic problem with the aggravating factor of being able to limit individual capacity, leading to a condition of unproductiveness and incapacity. At present, there is no effective treatment for recovering an injured spinal cord. Our research group was one of the pioneers in the study of mesenchymal stem cell therapies in the treatment of SCI, having carried out preclinical studies, as well as clinical studies with participants with complete spinal cord injuries, which demonstrated that stem cell transplantation mesenchymal (MSC) from autologous bone marrow was a safe and effective therapy in these studies. This project proposes the investigation of this therapy in participants with complete spinal cord injuries in the thoracolumbar region, in the subacute phase (defined between 3 to 6 months after the event), aiming to evaluate the safety and efficacy of the injection of mesenchymal stem cells. For this, we propose a double-blind, randomized clinical study to demonstrate the efficacy and safety of bone marrow MSC transplantation in participants with complete paraplegia, classified by ASIA Impairment Scale (AIS) grade A, by TRM, with subacute lesion. Forty participants will be referred by reference institutions and then recruited to be subsequently subjected to randomization, if eligible, with a group of 20 participants treated by intrathecal infusion of autologous MSCs, and another of 20 participants allocated to the control group, using a glucophysiological solution as a subcutaneous placebo. Each participant, after recruitment, will be monitored for a period of approximately 01 (one) year. The preparation of the CTMs will be done in accordance with the standards of good manufacturing practices. Both groups participating in the study will be submitted to pre- and post-treatment evaluations. The effectiveness of the therapy will be evaluated using the scale established by ASIA (American Spinal Injury Association) and the International Classification of Functioning, Disability and Health (ICF).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: December 1, 2023
• Est. primary completion date: September 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Both sexes over 18 years old;
• Closed or open spinal cord injury at the thoracic or lumbar level in the subacute phase (between 3 and 6 months after the event);
• ASIA A rating.

Exclusion Criteria:

• Section of the spinal anatomy;
• Active infectious diseases;
• Terminal patients;
• Neurodegenerative diseases;
• Primary hematologic diseases;
• Bone reflecting increased risk for spinal puncture;
• Coagulopathies;
• Hepatic dysfunction;
• Pregnancy;
• Other medical complications that contraindicate surgery, including major respiratory complications;
• Participation in another clinical trial;
• Use of metal implants close to vascular structures (such as cardiac pacemaker or prosthesis) that contraindicate magnetic resonance

Related Conditions & MeSH terms

• Spinal Cord Injuries
• Wounds and Injuries

Intervention

Genetic:
• Mesenchymal stem cell transplantation
Patients will undergo two autologous bone marrow stem cell transplantation into the lesion area

Other:
• Placebo
Patients will undergo two subcutaneous injections of 1 ml of glycophysiological solution into the lesion area by sham procedure

Locations

Country	Name	City	State
Brazil	Senai Cimatec	Salvador	Bahia

Sponsors (5)

Lead Sponsor	Collaborator
SENAI CIMATEC	Federal University of Bahia, Hospital da Bahia, Hospital Geral do Estado, Oswaldo Cruz Foundation

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline ASIA scale and 12 Months after autologous mesenchymal stem cells transplantation in individuals with subacute spinal cord injury	The International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI), commonly referred to as the ASIA Exam, was developed by the American Spinal Injury Association (ASIA) as a universal classification tool for spinal cord injuries based on a standardized sensory and motor assessment.It involves both a Motor and Sensory examination to determine the Sensory Level and Motor Level for each side of the body (Right and Left), the single Neurological Level of Injury (NLI) and whether the injury is Complete or Incomplete. Elements of the scale include: Grade A: The impairment is complete, Grade B ,C and D: The impairment is incomplete with some differences between them.;Grade E: The patient's functions are normal	Baseline and 12 months
Secondary	Change from Baseline AIS scale and 12 Months after autologous mesenchymal stem cells transplantation	American Spinal Injury Association Impairment Scale (AIS) is a standardized neurological examination used by the rehabilitation team to assess the sensory and motor levels which were affected by the spinal cord injury. The scale has five classification levels, ranging from complete loss of neural function in the affected area to completely normal. The results help the team set functional goals based on the neurological level of injury that is determined. Elements of the scale include: Grade A: The impairment is complete, Grade B ,C and D: The impairment is incomplete with some differences between them.;Grade E: The patient's functions are normal.	Baseline and 12 months
Secondary	Improvement in quality of life, measured by the WhoQof-bref Questionnaire.	The WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health (7 items), psychological health (6 items), social relationships (3 items), and environmental health (8 items); it also contains QOL and general health items. Each individual item of the WHOQOL-BREF is scored from 1 to 5 on a response scale, which is stipulated as a five-point ordinal scale. The scores are then transformed linearly to a 0-100-scale	Baseline, 1 month, 6 months and 12 months
Secondary	Assessment of neuropathic pain by McGill Pain Questionnaire	McGill Pain Questionnaire (MPQ) is a self-reporting measure of pain used for patients with a number of diagnoses. It assesses both quality and intensity of subjective pain. The MPQ is a multi-dimesional tool for pain assessment and it has three components, which are the sensory intensity, the cognitive evaluation of pain and the emotional impact of pain.	Baseline, 1 month, 6 months and 12 months
Secondary	Assessment sensory impairment after subacute spinal cord injury with von Frey filaments	The mechanical sensitivity (Von Frey) test consists of thin calibrated plastic filaments that are applied to the plantar surface. Von Frey filaments of different gauges or stiffness are used to determine the threshold that elicits a hind paw withdrawal response. The mechanical withdrawal threshold is defined as the minimum gauge Von Frey filament that elicits a withdrawal reflex. The purpose of this test is to measure mechanical nociception in order to valuates the ability to detect a noxious stimulus.	Baseline, 1 month, 6 months and 12 months
Secondary	Assessment sensory impairment after subacute spinal cord injury with Quantitative Sensory Test	Quantitative sensory testing (QST) refers to psychophysical tests of sensory perception during the administration of stimuli with predetermined physical properties and following specific protocols. QST is able to capture and quantify stimulus-evoked negative and positive sensory phenomena,	Baseline, 1 month, 6 months and 12 months